Business
ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
ImmunityBio’s COVID-19 vaccine candidate was selected for Operation Warp Speed, a national program to accelerate COVID-19 vaccine development. Candidate is
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nImmunityBio’s COVID-19 vaccine candidate was selected for Operation Warp Speed, a national program to accelerate COVID-19 vaccine development. Candidate is the first human adenovirus (Ad5) vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA for potential long-lasting humoral and cell-mediated immunity\n\n\nNantKwest and ImmunityBio have signed a binding term sheet for the joint development, manufacture and marketing of vaccines and therapeutics for COVID-19\n\n\nFDA authorization of 2nd generation human adenovirus (Ad5-Covid-S/N) vaccine candidate anticipated in June 2020, trials to follow\n\n\nNantKwest GMP manufacturing plant available to produce vaccine at scale\n\n\nFDA authorized ImmunityBio’s IL-15 Investigational New Drug application for treating patients at different stages of COVID-19 infection \n\n\n EL SEGUNDO, Calif.--(BUSINESS WIRE)--\nNantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected to participate in Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Efforts will focus on the development, testing, and large-scale manufacturing of ImmunityBio’s COVID-19 human adenovirus vaccine (hAd5) candidate. This is the first vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA, offering the potential for patients to develop long-lasting immunity to the virus.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005680/en/\n\nThis novel, E1, E2b, E3 deleted, human adenovirus vector has demonstrated safety in over 125 patients in 13 Phase 1 and 2 trials to date. Clinical studies performed by the National Cancer Institute have demonstrated that this novel Ad5 may induce antigen-specific T-cell immunity in patients, even in the presence of pre-existing adenoviral immunity.\n\n\nThe companies also announced that the U.S. Food and Drug Administration (FDA) has authorized the use of ImmunityBio’s IL-15 (generic name nogapendekin alfa inbakicept) to treat patients prior to the onset of severe disease by potentially activating natural killer cells to mitigate viral replication. On May 18, NantKwest ann...